Aug. 19 at 6:35 PM
Baird reiterated
$SLNO Outperform-
$121 and said, 'Buyers on Pullback Following Short Report.'
$AARD $RYTM $ACAD $BIIB $RHHBY
Baird additionally said in its note:
The Soleno short report, published on Friday, claims Vykat is a ticking safety time bomb and that the PWS physician and patient communities are generally averse to trying Vykat, both of which we think are sensationalized.
We live in the age of anecdotal evidence, so we don't want to underestimate the risk of some Facebook posts. However, we think the safety profile over hundreds of patients treated commercially remains consistent with the clinical trial experience, and we expect the impressive early growth to continue.
